(0.21%) 5 471.80 points
(0.17%) 39 187 points
(0.62%) 17 842 points
(2.11%) $83.26
(-3.77%) $2.50
(0.01%) $2 339.80
(1.34%) $29.63
(-2.34%) $990.40
(-0.15%) $0.932
(-0.13%) $10.66
(0.02%) $0.791
(1.05%) $86.63
FY/2024
Generated By Getagraph.com: 2024-03-31
VistaGen Therapeutics Inc [VTGN]
0.36% $ 3.49
Биржа: NASDAQ Сектор: Healthcare Промышленность: Biotechnology
VistaGen Therapeutics Inc (NASDAQ: VTGN) has reported its financial results for the fiscal year ending March 31, 2024. This period saw several key milestones in the company's clinical development programs, particularly around their neuroscience pipeline that promises innovative solutions for social anxiety disorder (SAD), major depressive disorder (MDD), and menopausal hot flashes.
Throughout fiscal year 2024, VistaGen has achieved remarkable milestones, most notably the positive results from the PALISADE-2 U.S. Phase 3 study. These results position VistaGen as the first company to achieve a positive Phase 3 study with a drug candidate for the acute treatment of SAD. The company has also successfully launched its PALISADE-3 Phase 3 trial, continuing its momentum in addressing this high-prevalence neuropsychiatric disorder.
For the fiscal year ending March 31, 2024, VistaGen reported:
VistaGen implemented several key enhancements to its clinical studies to ensure optimal results. These include rigorous training, optimized site staffing models, and introduction of exclusion criteria to limit variability and ensure quality enrollment. Such measures have shown substantial positive impact on the progress of the PALISADE-3 and PALISADE-4 trials.
During fiscal 2024, VistaGen made noteworthy advancements in its clinical development pipeline. In addition to the progress on PALISADE trials for fasedienol, the company is actively preparing for a U.S. Phase 2B study of itruvone for MDD. Additionally, they are exploring the medical and commercial potential of PH80 for treating menopausal hot flashes.
VistaGen remains committed to pioneering a new era in neuroscience with its neuroscience pipeline, focusing on high-prevalence CNS disorders. The company aims to close treatment gaps and set new standards of care, while systematically executing its registration-directed programs for potential FDA approvals. The anticipated top-line readouts from ongoing Phase 3 trials are expected by mid-year and end of calendar year 2025.
VistaGen's fiscal year 2024 showcased robust progress in both clinical development and financial management. The company remains well-positioned to enhance patient lives and deliver sustained value to shareholders. With a continued focus on innovation and operational excellence, VistaGen looks forward to achieving critical milestones in the coming years.
Revenues FY - 2024
Revenue | Gross Profit | Operating Expenses | Interest Expense | EBITDA | Net Income | EPS |
---|---|---|---|---|---|---|
$1.06M | $496 000 | $34.09M | $0 | $-33.02M | $-29.36M | $-1.520 |
Balance FY - 2024
Net Income | Depreciation and Amortization | Stock Based Compensation | Change in Working Capital | Net Cash Provided by Operating Activities | Capital Expenditure | Free Cash Flow |
---|---|---|---|---|---|---|
$-29.36M | $568 000 | $2.18M | $793 000 | $-25.81M | $-61 000.00 | $-25.87M |